Perimeter Medical Imaging AI (PINK) Planet MicroCap Showcase: TORONTO 2025 summary

Key product developments and technology

• Two products: S-Series (in market, revenue-generating) and B-Series (next-gen, under FDA review).

• Uses optical coherence tomography (OCT) for high-resolution, real-time imaging of tissue margins during cancer surgery.

• AI-powered software in B-Series highlights suspicious images, reducing surgeon learning curve and review time.

• Over 2 million breast tissue images collected, forming a unique, protected data library for training and future monetization.

• FDA Breakthrough Device Designation accelerates regulatory review; AI-enabled product expected to launch after approval in Q1.

Clinical impact and market opportunity

• Device reduces re-operation rates from national average of ~20% to 3-4% in commercial use.

• Repeat surgeries increase patient trauma, complications, and healthcare costs, with re-operations costing $20K–$100K.

• Improved first-surgery success rates significantly boost 5-year survival, especially in cancers beyond breast.

• Large addressable market: 250,000 breast cancer surgeries/year in the U.S., with expansion into lung, head/neck, and melanoma.

• Multi-billion dollar global opportunity, with multiple revenue streams from OR, biopsy, and pathology applications.

Commercialization, sales, and financials

• Initial business model: free device placement, revenue from single-use consumables (now >$1,000 each, 90%+ gross margin).

• Added direct cart sales (50% gross margin) and annual service contracts ($20K–$30K/year).

• AI software to be monetized as a high-margin add-on post-approval.

• Organic, surgeon-led demand drives adoption; minimal sales force with strong word-of-mouth growth.

• U.S. market focus, expanding from Dallas HQ, with plans to penetrate high-value Northeast and Great Lakes regions.